On Tuesday, European Union (EU) antitrust regulators conducted surprise inspections at a cardiovascular medical device company located within an EU member state. These actions were taken due to concerns that the company may have engaged in practices that abused its market dominance, potentially violating the EU’s antitrust regulations.
In an official statement, the EU’s competition enforcement body, the European Commission, confirmed these unannounced visits to the company’s premises. The statement explained that the Commission was investigating the company’s activities in the field of medical devices for cardiovascular applications and expressed concerns that the company might have breached EU antitrust rules prohibiting the misuse of a dominant market position.
The European Commission, serving as the antitrust authority for the 27 EU member countries, adhered to its policy of not disclosing the specific company or the country involved. It’s important to note that companies found to have violated EU antitrust laws can face fines of up to 10% of their global turnover.
These surprise inspections or ‘Dawn Raids’ are often among the first steps in the investigative process when there are suspicions of anticompetitive behavior. It should be noted that the Commission’s actions do not presuppose the company’s guilt regarding anticompetitive practices, nor do they predetermine the outcome of the ongoing investigation.
Related: EC Europa
Featured News
Subscribers Defend $4.7 Billion Antitrust Verdict Against NFL in Court Filings
Jul 19, 2024 by
CPI
Von der Leyen Calls for Competition Policy to Boost EU Companies’ Growth
Jul 19, 2024 by
CPI
Vermont AG Sues Pharmacy Benefit Managers Over Drug Prices
Jul 18, 2024 by
CPI
Australians Face Increased Stamp Prices Following ACCC Approval
Jul 18, 2024 by
CPI
Live Nation Seeks Dismissal of DOJ Antitrust Allegations
Jul 18, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Private Equity Roll-Up Schemes
Jun 28, 2024 by
CPI
The FTC’s Focus on Private Equity is Warranted
Jun 28, 2024 by
CPI
Unraveling the Roll-Up: Private Equity’s Misunderstood Investment Strategy
Jun 28, 2024 by
CPI
Antitrust Focus on Private Equity Funds and Serial Acquisitions
Jun 28, 2024 by
CPI
Private Equity Roll-Ups Amidst Heightened Antitrust Enforcement
Jun 28, 2024 by
CPI